title: Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
authors.forename: Arwa Z
authors.initials: AZ
authors.lastname: Al-Riyami
authors.forename: Monika
authors.initials: M
authors.lastname: Hudoba
authors.forename: Sean
authors.initials: S
authors.lastname: Young
authors.forename: Donna
authors.initials: D
authors.lastname: Forrest
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D000077157:Sorafenib; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; C479818:FIP1L1 protein, human; D010671:Phenylurea Compounds; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D020796:Receptor, Platelet-Derived Growth Factor alpha